Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Otulfi® (ustekinumab-aauz) by Fresenius Kabi Now FDA-Approved as an Interchangeable Biosimilar

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara® (ustekinumab)....

Kimera® Labs named a semifinalist in the $101 million XPRIZE Healthspan competition for pioneering innovations in healthy aging

Kimera Labs, Inc., the pioneer in therapeutic exosome biotechnology, is proud to announce its selection as a semifinalist in the prestigious $101 million XPRIZE Healthspan competition. This milestone recognizes Kimera's groundbreaking work in...

SK Life Science Labs Announces Nature Communications Publication of Breakthrough Molecular Glue Research Advancing Cancer Immunotherapy

SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for cancer and disorders of the central nervous system (CNS), announced the...

Element Science Receives FDA Approval for the Revolutionary Jewel® Patch Wearable Cardioverter Defibrillator

In a significant leap forward in the care of patients with cardiac disease, Element Science is proud to announce that its innovative Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD) has received U.S. Food and Drug Administration (FDA)...

Stablepharma Launches Phase 1 Trials for First-Ever Fridge-Free Tetanus & Diphtheria Vaccine

Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National...

Xencor Announces Promising Early Results for XmAb942 in First-in-Human Study Targeting IBD

Xencor, Inc.a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942. A high-potency,...

At the Longhorn Vaccines and Diagnostics Presents Compelling Data on the LHNVD-303 Vaccine for Sepsis Linked to Bacterial Infections

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial...

Serge Messerlian Appointed CEO of Creyon Bio, Leveraging Decades of Experience in Company Building and Strategic Collaborations

Creyon Bio, Inc. announced the appointment of industry leader, Serge Messerlian as Chief Executive Officer, effective immediately. Mr. Messerlian brings Creyon Bio a track record in both multinational pharmaceutical and biotechnology leadership as...

BioClear Toenail Fungus Device Under Review: Effective LED Laser for Healthy Nails & Discoloration Treatment

Toenail fungus, medically known as onychomycosis, is more than just a cosmetic issue. It's a persistent condition that affects the appearance, health, and comfort of your feet. What begins as a small yellow or white spot under the nail can...

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Distinct Payloads to Address Limitations of Current ADCs

HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer and other diseases, announced today it has filed two investigational new drug (IND) applications (HF158K1 and HFK2) with China’s National Medical...

VCU Collaboration Launched by Galmed Pharmaceuticals to Address Drug Resistance in GI Cancers

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company, announced a sponsored research collaboration with Virginia Commonwealth University (VCU) to investigate Aramchol's potential in overcoming drug resistance in gastrointestinal...

Daicel Arbor Biosciences and Element Biosciences announce a new grant opportunity, accelerating agrigenomics

Daicel Arbor Biosciences, a company that offers tools and services to accelerate genomics and synthetic biology research, in collaboration with Element Biosciences, a life sciences company democratizing access to advanced biological tools, is...

Pint Pharma secures ANVISA approval for BESREMi® to treat Polycythemia Vera

Pint Pharma and PharmaEssentia announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic,...

Developing innovative production technology for the commercialization of 3D cell products, PHC and Cyfuse collaborate

PHC Corporation a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. announce the successful development of a new production technology(*1) for the commercialization of...

Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial Reported by Blue Earth Therapeutics

Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy. Radiation dosimetry and pharmacokinetic data from the 13 metastatic castrate...

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a Phase 1 clinical trial of FZ002 for C. difficile treatment. Oral FZ002 is a live yeast genetically modified to express a...

A convenient and cost-effective way to treat sickle cell disease may be offered by Vascarta's patented transdermal drug candidate

An article in the Proceedings of the National Academy of Sciences (PNAS) Nexus journal* by Goel et al. describes studies in which humanized sickle cell mice topically treated with Vascarta's transdermal curcumin gel formulation ("VAS-101")...

"Grindeks, the leading pharmaceutical company in the Baltics, expands to new export markets worldwide

The leading pharmaceutical company in the Baltics, Grindeks, continues to strengthen its global presence by entering new export markets. This year, for the first time, Grindeks products will be delivered to Panama. The company's export markets...

New FDA-Cleared Treatment for Fibromyalgia Symptoms from Swing Therapeutics Covered by Highmark

Swing Therapeutics announced that Stanza, its digital therapeutic for treatment of fibromyalgia symptoms, has received a positive coverage decision from Highmark Health. Highmark’s commercial members across Pennsylvania, West Virginia, Delaware,...

Beacon Therapeutics has been granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation for laru-zova (AGTC-501)

Beacon Therapeutics Holdings Limited a leading ophthalmic gene therapy company with a mission to save and restore the vision of patients with blinding retinal diseases, announced that the U.S. Food and Drug Administration (FDA) has granted...